Savior Lifetec (4167) - Total Assets
Based on the latest financial reports, Savior Lifetec (4167) holds total assets worth NT$4.18 Billion TWD (≈ $131.82 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 4167 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Savior Lifetec - Total Assets Trend (2011–2025)
This chart illustrates how Savior Lifetec's total assets have evolved over time, based on quarterly financial data. See net assets of Savior Lifetec for net asset value and shareholders' equity analysis.
Savior Lifetec - Asset Composition Analysis
Current Asset Composition (December 2025)
Savior Lifetec's total assets of NT$4.18 Billion consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 19.7% |
| Accounts Receivable | NT$286.01 Million | 6.8% |
| Inventory | NT$573.38 Million | 13.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Savior Lifetec's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Savior Lifetec.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Savior Lifetec's current assets represent 61.1% of total assets in 2025, an increase from 46.1% in 2011.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2025, up from 9.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 13.7% of total assets.
Savior Lifetec Competitors by Total Assets
Key competitors of Savior Lifetec based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Savior Lifetec - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.06 | 4.71 | 5.52 |
| Quick Ratio | 8.58 | 3.73 | 3.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.32 Billion | NT$2.56 Billion | NT$2.10 Billion |
Savior Lifetec - Advanced Valuation Insights
This section examines the relationship between Savior Lifetec's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.54 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | NT$4.18 Billion |
| Market Capitalization | $165.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Savior Lifetec's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Savior Lifetec's assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Savior Lifetec (2011–2025)
The table below shows the annual total assets of Savior Lifetec from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$4.18 Billion ≈ $131.82 Million |
-4.39% |
| 2024-12-31 | NT$4.38 Billion ≈ $137.87 Million |
+14.48% |
| 2023-12-31 | NT$3.82 Billion ≈ $120.44 Million |
-13.29% |
| 2022-12-31 | NT$4.41 Billion ≈ $138.90 Million |
-2.86% |
| 2021-12-31 | NT$4.54 Billion ≈ $142.99 Million |
-6.16% |
| 2020-12-31 | NT$4.84 Billion ≈ $152.38 Million |
+19.92% |
| 2019-12-31 | NT$4.03 Billion ≈ $127.07 Million |
+14.28% |
| 2018-12-31 | NT$3.53 Billion ≈ $111.20 Million |
-10.59% |
| 2017-12-31 | NT$3.95 Billion ≈ $124.37 Million |
+14.87% |
| 2016-12-31 | NT$3.44 Billion ≈ $108.27 Million |
+5.90% |
| 2015-12-31 | NT$3.25 Billion ≈ $102.24 Million |
+3.60% |
| 2014-12-31 | NT$3.13 Billion ≈ $98.69 Million |
+13.32% |
| 2013-12-31 | NT$2.76 Billion ≈ $87.09 Million |
+16.24% |
| 2012-12-31 | NT$2.38 Billion ≈ $74.92 Million |
+1.91% |
| 2011-12-31 | NT$2.33 Billion ≈ $73.51 Million |
-- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more